SpaceX rocket explodes into fireball during routine test
Watch
A SpaceX rocket exploded into a massive fireball during a test flight in Texas. No injuries have been reported.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Is Increased Focus on Hypersonic Tech Opening New Doors for Rocket Lab?
In recent years, the rapid development and adoption of hypersonic technology across industries, from aerospace and defense to space exploration, have opened new growth avenues for Rocket Lab USA RKLB, a key player in hypersonic testing with its HASTE launch system. With commercial firms and government agencies ramping up investments in advanced hypersonic systems to bolster space access and national security, RKLB remains well-positioned to capitalize on this accelerating technological shift. Notably, Rocket Lab's HAEST (Hypersonic accelerator suborbital test electron) is a suborbital testbed launch vehicle that provides reliable, high-cadence flight test opportunities needed to boost hypersonic and suborbital system technology development. In April 2025, Rocket Lab secured a contract from Kratos Defense to conduct a full-scale hypersonic test flight for the U.S. Department of Defense. Additionally, RKLB's HASTE platform has been included in two major defense frameworks — the $46 billion Enterprise-Wide Agile Acquisition Contract with the U.S. Air Force and the UK Ministry of Defence's £1 billion ($1.3 billion) Hypersonic Technologies & Capability Development Framework. These programs allow Rocket Lab to compete for launch and engineering services in advancing hypersonic technologies. The inclusion across both U.S. and UK initiatives underscores the growing demand for HASTE in defense testing and is likely to significantly boost Rocket Lab's future revenue stream. While HASTE has not yet won any purely commercial contract, its demonstrated reliability and cadence in the defense sector may soon open doors to non-defense payload opportunities. Other Stocks Focusing on Hypersonic As increased investment in hypersonic technology has become a global trend lately, with nations like the United States, the United Kingdom, and China significantly boosting funding for research and development in this tech, other stocks like Lockheed Martin LMT and RTX Corp. RTX are also indulging in advanced hypersonic technology developments. Notably, Lockheed Martin has been developing highly advanced hypersonic technology for the past 60 years. To this end, the company is currently working in partnership with DARPA, the U.S. Air Force, the U.S. Army, and the U.S. Navy to transition hypersonic concepts to operational reality. LMT's Conventional Prompt Strike is a hypersonic boost-glide missile currently under development, which boasts the capability to provide longer range, shorter flight times, and high survivability against enemy defenses. On the other hand, RTX is working across its business and domains to move advanced hypersonic capabilities from creation to testing and into the hands of warfighters at top speed. RTX is currently involved in the design of the Hypersonic Attack Cruise Missile, which leverages Northrop Grumman's scramjet propulsion to travel at more than five times the speed of sound and cover vast distances in minutes. The U.S. Air Force currently expects this missile to be operational by fiscal 2027. The Zacks Rundown for RKLB Shares of RKLB have surged 467.2% in the past year compared with the industry 's 40.9% growth. The company's shares are trading at a premium on a relative basis, with its forward 12-month Price/Sales being 17.85X compared with its industry's average of 9.65X. The Zacks Consensus Estimate for RKLB's 2025 and 2026 earnings has improved over the past 60 days. RKLB currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Lockheed Martin Corporation (LMT): Free Stock Analysis Report Rocket Lab Corporation (RKLB): Free Stock Analysis Report
Globe and Mail
an hour ago
- Globe and Mail
FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention
Gilead Sciences, Inc. GILD obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the prevention of HIV. The regulatory body approved lenacapavir, under the brand name Yeztugo, for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg. This groundbreaking injectable therapy marks the first and only twice-yearly PrEP option available in the United States. The FDA nod, granted under Priority Review, was based on extraordinary data from the late-stage studies, PURPOSE 1 and PURPOSE 2, which showed that ≥99.9% of participants who received Yeztugo remained HIV-negative. Year to date, shares of GILD have gained 18.6% against the industry 's decline of 4%. More on GILD's Yeztugo The approval of Yeztugo for HIV prevention is a major breakthrough in the fight against HIV epidemic. At present, there are two FDA-approved daily oral medications for PrEP — Truvada and Descovy. Both of these are marketed by GILD alone. Please note that Descovy for PrEP is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. Truvada is a two-drug combination of emtricitabine and tenofovir disoproxil fumarate, approved for the treatment of HIV-1 infection and PrEP. Data from PURPOSE 1 study showed that twice-yearly subcutaneous Yeztugo demonstrated zero HIV infections among 2,134 participants in the Yeztugo group, 100% reduction in HIV infections and superiority of prevention of HIV infections when compared with once-daily oral Truvada in cisgender women in sub-Saharan Africa. Data from the PURPOSE 2 study showed that 99.9% of participants in the Yeztugo group did not acquire HIV infection. Yeztugo was also superiority in preventing of HIV infections when compared with once-daily oral Truvada among a broad and geographically diverse range of cisgender men and gender-diverse people. Yeztugo also demonstrated superiority of prevention of HIV infections when compared with background HIV incidence (bHIV) and was generally well-tolerated, with no significant or new safety concerns identified. Yeztugo was also granted Breakthrough Therapy Designation in October 2024. The European Medicines Agency has also validated the Marketing Authorization Application for twice-yearly lenacapavir for HIV prevention. Yeztugo Approval – A Significant Boost for GILD As the first long-acting injectable PrEP administered just twice a year, Yeztugo addresses persistent barriers that have limited broader PrEP adoption, such as challenges with daily oral PrEP, adherence, stigma and healthcare access. This approval represents a paradigm shift in HIV prevention and is expected to catalyze uptake among populations that have historically been underserved by existing prevention tools. Yeztugo has a competitive advantage as it needs to be taken only twice yearly, unlike daily oral pills, and addresses a broad population. Gilead has a market-leading portfolio of HIV treatments. Flagship drug Biktarvy accounts for over 51% share of the treatment market in the United States and should maintain momentum. The approval of Yeztugon solidifies its HIV portfolio as its other prevention drug, Truvada, faces generic competition. We note that lenacapavir is already approved in multiple countries for the treatment of adults with multi-drug resistant HIV in combination with other antiretrovirals. It is also approved in the United States to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, who are at risk of HIV acquisition. A long-acting injectable form of PrEP was also approved by the FDA. In 2021, the regulatory body approved ViiV Healthcare's Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kg for PrEP to reduce the risk of sexually acquired HIV. ViiV Healthcare is a global specialist HIV company, majorly owned by GSK plc GSK, with Pfizer and Shionogi as shareholders. The company was formed by GSK and Pfizer in 2009. Apretude is given first as two initiation injections, administered a month apart and then every two months. Patients in need can either start their treatment with Apretude or take oral cabotegravir (Vocabria) for four weeks to understand how well they can tolerate the drug. Approval of better HIV treatments should strengthen GILD's HIV franchise in the wake of increasing competition from the likes of GSK. GSK's HIV portfolio sales are being driven by strong patient demand for Cabenuva, Apretude and Dovato. The company is also focused on the development of the next generation of HIV innovation with integrase inhibitors (INSTIs) for HIV treatment and prevention. GILD's Zacks Rank and Stocks to Consider Gilead currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Novartis NVS and Bayer BAYRY, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for Novartis' 2025 earnings per share (EPS) has risen from $8.53 to $8.74 over the past 60 days. EPS estimates for 2026 have jumped 23 cents to $9.02 during this timeframe. The stock has risen 22% so far this year. BAYRY's 2025 EPS estimate has increased from $1.19 to $1.25 for 2025 over the past 60 days, while that for 2026 has gone up from $1.28 to $1.31 over the same timeframe. Year to date, shares of Bayer have surged 59.8%. BAYRY's earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report
Globe and Mail
an hour ago
- Globe and Mail
Ibogaine by David Dardashti Takes Center Stage on Day One of Psychedelic Science Conference 2025, Emphasizing Collaboration, Education, and Industry Synergy
DENVER, CO - June 19, 2025 - Ibogaine by David Dardashti, a leading initiative in ibogaine research and advocacy, today commenced its participation in the highly anticipated Psychedelic Science Conference 2025 in Denver, Colorado. As the conference officially began its main programming today, June 18th, the presence of Ibogaine by David Dardashti marks a pivotal moment for the burgeoning field of psychedelic medicine, championing a collaborative approach to advance ibogaine's therapeutic potential, particularly in the realm of addiction treatment. On this crucial first day of the conference, which runs from June 16-20, 2025 (with workshops on June 16th and 17th preceding the main conference), representatives of Ibogaine by David Dardashti are engaging with a diverse array of stakeholders, focusing on three key areas: potential collaborations with integration-based psychedelic therapies, offering internship opportunities to students of psychedelic studies, fostering synergy with other industries for enhanced news exposure within the psychedelic sub-sector. "The future of psychedelic medicine, especially ibogaine, lies in our collective ability to integrate these powerful experiences into comprehensive, supportive care models," stated David Dardashti, the driving force behind Ibogaine by David Dardashti. "Our discussions here at Psychedelic Science 2025 are centered on forging partnerships with organizations dedicated to integration-based therapies. It's not enough to simply administer a compound; we must ensure individuals receive the robust psychological and spiritual support necessary to process and implement the profound insights gained from their ibogaine journeys." Recognizing the critical need for a skilled workforce in this evolving field, Ibogaine by David Dardashti is also actively promoting internship opportunities for students pursuing psychedelic studies. "The next generation of researchers, therapists, and advocates will be instrumental in shaping the trajectory of psychedelic medicine," Dardashti emphasized. "We are committed to providing hands-on experience and mentorship to talented students, empowering them to contribute meaningfully to this vital area of healthcare." These internships aim to bridge the gap between academic learning and practical application, offering students invaluable exposure to clinical research, patient care, and policy development related to ibogaine. Furthermore, Ibogaine by David Dardashti is keen to expand the reach and understanding of ibogaine within the broader public discourse. The initiative is exploring collaborations with media and other industries to facilitate greater news exposure for the psychedelic sub-sector. "Accurate and responsible media representation is paramount to dispelling misconceptions and fostering public acceptance of psychedelics as legitimate therapeutic tools," Dardashti noted. "By partnering with key industry players, we can ensure that the scientific advancements and profound patient stories surrounding ibogaine receive the attention they deserve, moving beyond sensationalism to substantive reporting." The engagements of Ibogaine by David Dardashti at Psychedelic Science 2025, particularly on this opening day of the main conference, underscore its commitment to fostering a holistic and collaborative ecosystem for ibogaine's integration into mainstream medicine. The initiative's vision extends beyond singular research efforts, encompassing a comprehensive strategy for patient support, professional development, and public education, all crucial elements for the responsible and effective rollout of psychedelic-assisted therapies. About Ibogaine by David Dardashti: Ibogaine by David Dardashti is a renowned initiative led by David Dardashti, dedicated to exploring ibogaine's potential in treating addiction and other mental health challenges. With a deep commitment to ethical practices and patient well-being, the initiative champions a holistic approach to psychedelic therapy, emphasizing the importance of integration and ongoing support.
